Is Right Ventricle-Pulmonary Artery (RV-PA) Coupling Important in Low Risk TAVR?

TAVR has long been an effective strategy to treat aortic stenosis. However, ventricular damage starts further before symptom onset, also affecting the left ventricle, pulmonary vessels, the right ventricle, the tricuspid valve, and the right atrium. 

La enfermedad vascular periférica se asocia a más eventos en el TAVI

It increases arterial afterload and uncouples the right ventricle and the pulmonary artery, defined by transthoracic echocardiogram as the relationship between the tricuspid annular plane systolic excursion (TAPSE) and  pulmonary artery systolic pressure (PASP), TAPSE/PSAP.

 A reduction in this relationship (≤0.55 mmHg) is associated with unfavorable evolution.

The study looked at PARTNER 3 patients. 222 of these patients (38.9%) presented RV-PA uncoupling TAPSE/PSAP ≤0.55 mmHg; and 348, RV-PA coupling TAPSE/PSAP >0.55 mmHg.

Primary end point was a composite of all cause death, stroke and rehospitalization at 2 years. 

Lea tambien: Should We Start Using Ultra-Thin Struts?

The populations were similar, mean age was 74, 66% were men, 30% were diabetic. Those presenting uncoupling had more arrythmia and higher BMP. 

After two years, primary end point was higher among those presenting uncoupling (19.1% vs 9.9%; HR: 2.03; 95% CI: 1.29-3.19; P=0.002), as was all cause (5.9% vs 0.6%; P < 0.001), and cardiovascular mortality (4.1% vs 0.6%; P=0.003) and rehospitalization (13.5% vs 7.3% P=0.02). Stroke rate (24.2% vs 14.2%; HR: 1.83; 95% CI: 0.98-3.41; P ¼ 0.053ke) was fairly low, with no difference.

Uncoupled patients undergoing transcatheter aortic valve replacement had a higher incidence of primary end point (24.2% vs 14.2% P=0.05).

Read also: Devices to Prepare Severely Calcified Lesions: Is There a Difference When Assessed by Intravascular Imaging?

At multivariable analysis, uncoupling resulted an independent predictor of primary end point at 2 years. 

Conclusion

In low risk symptomatic aortic stenosis patients undergoing TAVR or SAVR, baseline right ventricle and pulmonary artery uncoupling, defined as TAPSE/PSAP ≤0.55 mmHg, was associated to clinical adverse events at 2 years, including all cause and cardiovascular mortality, and rehospitalization. 

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the Editorial Board of SOLACI.org.

Original Title: Impact of Right Ventricle-Pulmonary Artery Coupling on Clinical Outcomes in the PARTNER 3 Trial.

Reference: Thomas J. Cahill, et al. J Am Coll Cardiol Intv 2022;15:1823–1833.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Management of Valve Thrombosis in TAVI: Current Evidence-Based Approach

The expansion of transcatheter aortic valve implantation (TAVI) into younger and lower-risk populations has brought bioprosthetic valve thrombosis to the forefront as a clinically...

Experience with the intra-annular self-expanding Navitor valve: data from the STS/ACC TVT registry

The expansion of TAVI, with the introduction of new-generation devices, has prioritized not only periprocedural safety, but also the preservation of coronary access, more...

ACC 2026 | Extended follow-up of the TRI-FR study: Edge-to-edge percutaneous repair in isolated severe tricuspid regurgitation

Severe tricuspid regurgitation (TR) is associated with chronic systemic venous congestion, recurrent hospitalizations for heart failure (HF), and a significant deterioration in quality of...

Coronary revascularization before TAVI: prior PCI or conservative management?

The coexistence of coronary artery disease (CAD) in patients with severe aortic stenosis undergoing TAVI is common, with a reported prevalence ranging from 30%...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

High Ischaemic Risk Criteria in Chronic Coronary Syndrome: Prevalence and Prognosis

Despite advances in the management of chronic coronary syndrome (CCS), including the widespread use of drug-eluting stents (DES) and the optimization of medical therapy,...

Management of Valve Thrombosis in TAVI: Current Evidence-Based Approach

The expansion of transcatheter aortic valve implantation (TAVI) into younger and lower-risk populations has brought bioprosthetic valve thrombosis to the forefront as a clinically...

Experience with the intra-annular self-expanding Navitor valve: data from the STS/ACC TVT registry

The expansion of TAVI, with the introduction of new-generation devices, has prioritized not only periprocedural safety, but also the preservation of coronary access, more...